Crohn’s drugs not linked to cancer

Use of anti-TNF drugs such as infliximab do not raise the risk of cancer in Crohn’s patients, say US researchers.

Data from over 6,000 Crohn’s patients from the TREAT registry showed that neither infliximab alone, nor immunosuppressive therapy alone, nor a combination of the two was independently associated with the risk of later cancer.

However disease duration, age and smoking status were all positively linked to cancer risk, the researchers from the University of Pennsylvania found.